OpenAI收购Orchestra Bio布局AI制药与临床运营
Many are asking whether AI investment will pay off. Here's a very good example o…
OpenAI通过并购深入垂直领域，展示AI在复杂科学研发中的实际落地能力，这对判断AI行业长期价值极具参考意义。
Many are asking whether AI investment will pay off. Here's a very good example of where AI is headed and why its more than a bubble:
许多人都在问，人工智能投资是否会有回报。这里有一个很好的例子，展示了人工智能的发展方向以及为何它不仅仅是一个泡沫：
OpenAI’s acquisition of Orchestra Bio adds agents that coordinate drug development, tracking how problems like a failed manufacturing batch could delay clinical trials. Paired with Rosalind, it shows toward a broader ambition: embedding AI across both scientific research and the operational work needed to bring medicines to patients.
OpenAI 收购 Orchestra Bio 后，获得了能够协调药物开发的智能体（agents），可以追踪诸如失败的制造批次如何导致临床试验延迟等问题。结合 Rosalind，这显示出更宏大的野心：将人工智能嵌入到科学研究以及将药物带给患者所需的运营工作中。
Drug research and disease cure are among the significant fields in which AI extends and will make tremendous progress. Anthropic published something similar today.
药物研发和疾病治愈是人工智能正在扩展并将取得巨大进展的重要领域之一。Anthropic 今天也发布了类似的内容。
更进一步：量化金融体系
看懂新闻只是起点——沿量化金融路径，把它变成能交付的工程能力